Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $8.50 Analyst target: $29.66 Upside: 248.94%
Kazia Therapeutics Limited, a biotechnology company focused on oncology, develops anticancer drugs. The company is headquartered in Sydney, Australia.
See the full interactive analysis & chart →Informational only — not investment advice.